Medical cannabis program ; product labels; delivery. Changes the requirements for what is included on medical cannabis product labels affixed by pharmaceutical processors to include (i) the total milligrams of tetrahydrocannabinol and cannabidiol included in the edible cannabis product or topical cannabis product, both defined in the bill; (ii) the number of milligrams of tetrahydrocannabinol and cannabidiol in each serving of the edible cannabis product or topical cannabis product; and (iii) the total percentage of tetrahydrocannabinol and cannabidiol included in the inhalable cannabis product, defined in the bill. Under current law, the product label of any medical cannabis product is required to include the total percentage and milligrams of tetrahydrocannabinol and cannabidiol included in the product and the number of milligrams of tetrahydrocannabinol and cannabidiol in each serving. The bill also allows a pharmaceutical processor or cannabis dispensing facility to dispense or deliver cannabis products in person to a patient or such patient's registered agent, parent, or legal guardian at any residence, including a temporary residence, or business. However, the bill prohibits dispensing or delivering cannabis products to any public gathering places, including sporting events, festivals, fairs, races, concerts, and terminals of public transportation companies.

Statutes affected:
Introduced: 4.1-1600, 4.1-1602, 4.1-1603
General Laws Subcommittee Substitute : 4.1-1600, 4.1-1602, 4.1-1603
Rehabilitation and Social Services Substitute: 4.1-1600, 4.1-1602, 4.1-1603